Long-Term Comparative Study on the Local Tumour Control of Different Ablation Technologies in Primary and Secondary Liver Malignancies.
cryoablation
electrochemotherapy
interstitial brachytherapy
interventional oncology
local ablative techniques
local tumour control
microwave ablation
personalised medicine
radiofrequency ablation
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
09 Mar 2022
09 Mar 2022
Historique:
received:
21
01
2022
revised:
16
02
2022
accepted:
03
03
2022
entrez:
25
3
2022
pubmed:
26
3
2022
medline:
26
3
2022
Statut:
epublish
Résumé
Purpose: To evaluate local tumour control (LTC) by local ablation techniques (LAT) in liver malignancies. Materials and methods: In patients treated with LAT between January 2013 and October 2020 target lesions were characterised by histology, dimensions in three spatial axes, volume, vascularisation and challenging (CL) location. LAT used were: Radiofrequency Ablation (RFA), Microwave Ablation (MWA), Cryoablation (CRYO), Electrochemotherapy (ECT), and Interstitial Brachytherapy (IBT). Results: 211 LAT were performed in 155 patients. Mean follow-up including MRI for all patients was 11 months. Lesions treated with ECT and IBT were significantly larger and significantly more often located in CL in comparison to RFA, MWA and CRYO. Best LTC (all data for 12 months are given below) resulted after RFA (93%), followed by ECT (81%), CRYO (70%), IBT (68%) and MWA (61%), and further, entity-related for HCC (93%), followed by CRC (83%) and BrC (72%), without statistically significant differences. LTC in hypovascular lesions was worse (64%), followed by intermediate (82% p = 0.01) and hypervascular lesions (92% p = 0.07). Neither diameter (<3 cm: 81%/3−6 cm: 74%/>6 cm: 70%), nor volume (<10 cm3: 80%/10−20 cm3: 86%/>20 cm3: 67%), nor CL (75% in CL vs. 80% in non CL) had a significant impact on LTC. In CL, best LTC resulted after ECT (76%) and IBT (76%). Conclusion: With suitable LAT, similarly good local tumour control can be achieved regardless of lesion size and location of the target.
Identifiants
pubmed: 35330429
pii: jpm12030430
doi: 10.3390/jpm12030430
pmc: PMC8951445
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Semin Intervent Radiol. 2017 Jun;34(2):145-166
pubmed: 28579683
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Cardiovasc Intervent Radiol. 2014 Feb;37(1):154-64
pubmed: 23670568
World J Clin Oncol. 2021 Sep 24;12(9):725-745
pubmed: 34631439
Hepatol Int. 2016 Nov;10(6):883-892
pubmed: 27126821
Biomed Res Int. 2018 Jan 21;2018:2178469
pubmed: 29581964
Gastrointest Tumors. 2016 Oct;3(2):90-102
pubmed: 27904861
BMJ Open. 2018 Oct 21;8(10):e025896
pubmed: 30344183
Gastroenterol Res Pract. 2015;2015:670965
pubmed: 26798332
Diagnostics (Basel). 2021 Mar 24;11(4):
pubmed: 33805107
J Immunother Cancer. 2017 Oct 17;5(1):78
pubmed: 29037259
PLoS One. 2015 Oct 06;10(10):e0139921
pubmed: 26441328
Radiology. 2013 Jul;268(1):89-97
pubmed: 23440327
World J Gastroenterol. 2021 Nov 21;27(43):7462-7479
pubmed: 34887643
Clin Transl Oncol. 2020 May;22(5):647-662
pubmed: 31359336
J Clin Med. 2021 Nov 26;10(23):
pubmed: 34884275
Int J Hyperthermia. 2019;36(1):36-43
pubmed: 30489175
Liver Cancer. 2015 Dec;4(4):208-14
pubmed: 26734576
J Oncol. 2019 Sep 16;2019:6298502
pubmed: 31636667
Semin Intervent Radiol. 2020 Dec;37(5):484-491
pubmed: 33328704
Front Oncol. 2021 Jun 29;11:671327
pubmed: 34268114
Oncologist. 2019 Oct;24(10):e990-e1005
pubmed: 31217342
Ann Oncol. 2016 Aug;27(8):1386-422
pubmed: 27380959
Cancers (Basel). 2020 Jan 08;12(1):
pubmed: 31936319
J Natl Cancer Inst. 2017 Sep 1;109(9):
pubmed: 28376151
J Contemp Brachytherapy. 2019 Dec;11(6):589-600
pubmed: 31969919
BMJ Open. 2019 Dec 23;9(12):e031741
pubmed: 31874875
BMJ Open. 2017 Sep 27;7(9):e016360
pubmed: 28963286
Cancer Treat Rev. 2012 Feb;38(1):54-62
pubmed: 21726960
Radiol Oncol. 2022 Feb 11;56(1):102-110
pubmed: 35148468
J Clin Transl Hepatol. 2018 Jun 28;6(2):175-188
pubmed: 29951363
Front Oncol. 2021 Apr 01;11:616058
pubmed: 33869002